Joe Hazleton
President & Chief Operating Officer
Replay available
Dyadic International, Inc. (DYAI) Q3 2025 Earnings Call
Dyadic International, Inc. (NASDAQ: DYAI) Q3 2025 earnings conference call, held 2025-11-12. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Mark Emelfarb
Chief Executive Officer
Ping Rawson
Chief Financial Officer
John Vandermolsten
Analyst, SACS
Tony Bowers
Analyst, IntroAct
Matt Hewitt
Analyst, Craig Hallam Capital
Robert Hoffman
Analyst, Princeton Opportunity Management
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Dyadic International, Inc..
Replay transcript excerpt
WEBVTT 00:00:01.280 -- 00:00:06.586 Good evening, and welcome to Dyadic International's Q3 2025 00:00:06.586 -- 00:00:11.471 conference call. Currently, all participants are in a listen-only mode. 00:00:11.471 -- 00:00:16.517 Following management's prepared remarks, there will be a brief question-and-answer session. 00:00:16.517 -- 00:00:21.883 As a reminder, this conference call is being recorded today, November 12, 2025. 00:00:21.883 -- 00:00:24.986 I would now like to turn the call over to Ms. 00:00:24.986 -- 00:00:27.389 Peng Rawson, 00:00:27.389 -- 00:00:31.351 Dyadic's Chief Financial Officer. Please go ahead. 00:00:31.351 -- 00:00:36.537 Thank you. Good evening and welcome everyone to Dyadic's Q3 2025 00:00:36.537 -- 00:00:42.164 conference call. I hope you have had the opportunity to review Dyadic's press releases 00:00:42.164 -- 00:00:47.788 announcing financial results for the quarter ended September 30, 2025. 00:00:48.091 -- 00:00:53.117 You may access our release and form 10Q and their investor session of the company's 00:00:53.117 -- 00:00:55.820 website at dyadic.com. 00:00:55.820 -- 00:01:00.724 On today's call, our president and chief operating officer, Joe Hazleton, will give a 00:01:00.724 -- 00:01:06.149 review of our Q3 2025 business and corporate highlights and provide 00:01:06.149 -- 00:01:10.333 a commentary on the strategic direction of the business. 00:01:10.333 -- 00:01:15.538 Our CEO, Mark Emelfarb, will provide an update on our biopharmaceutical 00:01:15.538 -- 00:01:20.863 programs, and I will follow with a review of our financial results in more detail, 00:01:20.863 -- 00:01:25.621 after which we'll hold a brief question and answer session. 00:01:25.621 -- 00:01:30.788 At this time, I would like to inform you that certain commentary made...